Bepirovirsen reduced posttreatment markers of hepatitis B infection at 72 weeks, with 20% of recipients achieving functional ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, ...

In patients with chronic hepatitis B infection, bepirovirsen achieves significantly higher rates of functional cure than placebo after discontinuation of nucleoside or nucleotide analog therapy.

Twenty-four weeks of bepirovirsen achieves a functional cure in approximately one-fifth of patients with chronic hepatitis B.

-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of drugs, its luck ...

Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The ...

Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from ...

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 Virion ...

A large percentage of US patients eligible for HBV treatment remain untreated, despite effective therapies reducing adverse outcomes like cirrhosis and hepatocellular carcinoma. Disparities in HBV ...

ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...